Rheumatoid Arthritis|Inhibitors Agonists Modulators Antagonists|HmoBio.com

Request The Product List ofRheumatoid Arthritis Rheumatoid Arthritis

Arthritis is an inflammatory disease of the joints, including the synovium, cartilage, bone, and supporting tissues. It is the leading cause of disability in the US and there are over 100 different types of the disease. The most common types of arthritis are osteoarthritis, rheumatoid arthritis and gout.

Damage to cartilage can lead to the degenerative condition called osteoarthritis. Contributing factors to this may include ageing, obesity, diabetes, injury or inflammatory diseases. The main symptoms of osteoarthritis are pain, stiffness and loss of mobility and function in the joints.

Rheumatoid arthritis is a condition concerning the immune system attacking the body's own tissues. Cytokinespromote the pathogenesis of the condition by maintaining chronic inflammation and driving the degradation of adjacent joint tissue. Macrophages, mast cells, T and B cells accumulate in the synovium which becomes inflamed and infiltrates the surrounding cartilage. This promotes articular destruction, which is mediated by osteoclasts, chondrocytes and synovial fibroblasts. In addition, new blood vessels are created by angiogenesisto supply the hypoxic joint with nutrients.

Arthritis is a debilitating condition which can cause sufferers a great deal of pain. This may be alleviated by certain medications or, in extreme cases, joint replacement surgery.

Cat. No.	Product Name	CAS No.	Information
H9361	Copanlisib	1032568-63-0	BAY-1830839 is a potent and selective IRAK4 inhibitor with IC50 values of 3 nM respectively.
H9130	Eclitasertib	2125450-76-0	Eclitasertib is a potent RIPK1 protein inhibitor useful in treatment of RIPK1-mediated diseases.
H8994	DMI 9523	397847-46-0	DMI 9523 is a nuclear factor NF-κB activation inhibitor. DMI 9523 is a naturally occurring anti-inflammatory compound that is under development for the treatment of osteoarthritis of the knee.
H8971	SHR-0302 sulfate	1639419-51-4	SHR0302 sulfate(Ivarmacitinib) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects.
H8970	SHR-0302	1445987-21-2	SHR0302(Ivarmacitinib) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects.
H8774	Aldumastat	1957278-93-1	Aldumastat is a novel ADAMTS inhibitor, for the treatment of osteoarthritis and their preparation.
H8737	Elsubrutinib	1643570-24-4	Elsubrutinib(ABBV-105,ABBV105) is a potent, selective, irreversible, covalent inhibitor of BTK with IC50 of 0.18 uM; irreversibly inhibits BTK, demonstrating superior kinome selectivity and is potent in B cell receptor, Fc receptor, and TLR-9-dependent cellular assays; inhibits antibody responses to thymus-independent and thymus-dependent antigens, paw swelling and bone destruction in rat collagen induced arthritis (CIA), and reduced disease in an IFNα-accelerated lupus nephritis model.
H8024	R788 free base	901119-35-5	Fostamatinib (R788) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM; dose-dependently inhibits anti-IgE-mediated CHMC degranulation with an EC50 of 56 nM, inhibits all phosphorylation events downstream of Syk signaling; specifically inhibits FcγR signaling in human mast cells, macrophages, and neutrophils. R788 can inhibit local inflammatory injury mediated by immune complexes; reduces immune complex-mediated inflammation in arthritis models.
H8023	R788 disodium hexahydrate	914295-16-2	Fostamatinib (R788) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM; dose-dependently inhibits anti-IgE-mediated CHMC degranulation with an EC50 of 56 nM, inhibits all phosphorylation events downstream of Syk signaling; specifically inhibits FcγR signaling in human mast cells, macrophages, and neutrophils. R788 can inhibit local inflammatory injury mediated by immune complexes; reduces immune complex-mediated inflammation in arthritis models.
H8014	Fostamatinib	1025687-58-4	Fostamatinib (R788 disodium salt) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM; dose-dependently inhibits anti-IgE-mediated CHMC degranulation with an EC50 of 56 nM, inhibits all phosphorylation events downstream of Syk signaling; specifically inhibits FcγR signaling in human mast cells, macrophages, and neutrophils. R788 can inhibit local inflammatory injury mediated by immune complexes; reduces immune complex-mediated inflammation in arthritis models.

Select Your Country or Region

Request The Product List ofRheumatoid Arthritis Rheumatoid Arthritis

Request The Product List

* Indicates a Required FieldYour information is safe with us.